ClinicalTrials.gg
CompletedNCT03399903Updated Mar 4, 2020

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

A Phase 1/2 interventional study of Pentasa vs Align in HIV-1-infection and Gut Inflammation, sponsored by AIDS Healthcare Foundation. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by AIDS Healthcare Foundation · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Mar 2019, 7 years 8 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled May 2017, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

An open label study will be performed on 80 people with HIV infection who are maintained on effective treatment with antiretroviral drugs.

Read the detailed description

The goal of this study is to test whether a bowel anti-inflammatory drug that is known to be safe and effective for inflammatory bowel disease would offer benefit in reducing the residual immune activation associated with treated HIV-1 infection. Specifically, the two immediate goals are to examine the safety of Pentasa® in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.

02

Conditions studied

  • HIV-1-infection
  • Gut Inflammation
03

In context

Lead sponsor

AIDS Healthcare Foundation is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at least 18
  • On ART for at least 1 year during which: viremia \<50 RNA copies/ml for at least 3 measurements (allowing for 1 nonconsecutive blip of \<100), and consistently >500 during that time
  • CD4 T cell nadir >350
  • Last CD4 and T cell test in past 6 months

Exclusion criteria

Exclusion Criteria:

  • Plans to modify antiretroviral therapy in the next 12 weeks for any reason
  • History of inflammatory bowel disease or irritable bowel disease
  • Chronic active or C
  • History of disease
  • to any component of Pentasa
  • Clostridium difficile infection
  • Receiving rectally delivered medications
  • Receiving anti-inflammatory medications (such as nonsteroidal anti- inflammatory drugs, , or TNF inhibitors)
  • Receiving steroids
  • Receiving any medications associated with bleeding risk
  • \< 10.0 g/dL
  • count less than 100,000/mm3
  • White blood cell count \< 2,000 cells/mm3 or > 15,000 cells/mm3
  • Symptoms of sexually transmitted infection
  • Antibiotics used in the last 90 days
  • Renal insufficiency with less than 50 ml/min
  • Elevated transaminases greater than 2.5 times the
  • Evidence of decompensated cirrhosis, heart failure
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Pentasa

    40 participants will be randomized to take 1 gram of Pentasa, twice daily for 8 weeks

    Drug: Pentasa vs Align

  • Active comparator
    Align

    40 participants will be randomized to take Align tablets, once daily for 8 weeks

    Drug: Pentasa vs Align

Interventions

  • DrugPentasa vs Align

    We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.

06

What researchers measure

Primary outcomes

  1. Inflammation markers

    C-reactive protein

    Time frame: 14 weeks

Secondary outcomes

  1. Flow cytometry for cellular immune activation

    Immune activation

    Time frame: 14 weeks

  2. Plasma markers of microbial translocation

    Microbial translocation

    Time frame: 14 weeks

07

Study locations

1 site
  • AIDS Healthcare Foundation - Public Health Division
    Los Angeles, California 90027, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Mar 2019, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 17, 2018
StartActual
May 1, 2017
Primary completionActual
Mar 22, 2019
CompletionActual
Mar 22, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03399903
Lead sponsor
AIDS Healthcare Foundation
Collaborators
HIV Immunotherapeutics Institute
Responsible party
Sponsor
First posted
Jan 17, 2018
Start date
May 1, 2017
Primary completion
Mar 22, 2019
Completion
Mar 22, 2019
Last update
Mar 4, 2020

Study contacts

Otto O Yang, MD
study director · AIDS Healthcare Foundation - HIV Immunotherapeutics Institute
Peter Anton, MD
principal investigator · AIDS Healthcare Foundation - HIV Immunotherapeutics Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion